Related Experiment Videos
The rational use of platelet transfusions in children
1Regional General Hospital, Dooradoyle, Limerick, Republic of Ireland.
Insights
Platelet transfusions effectively stop bleeding in children but are overused. Evidence suggests lower platelet count thresholds may be as effective and safer, especially in certain pediatric conditions.
Area of Science:
- Pediatric Hematology
- Transfusion Medicine
- Oncology
Background:
- Platelet transfusions are vital for hemostasis in children with platelet dysfunction.
- Overuse of platelet transfusions occurs, particularly in pediatric oncology.
- Current practices carry risks, including alloimmunization and infection transmission.
Purpose of the Study:
- To evaluate the evidence supporting prophylactic platelet transfusions in children.
- To assess the safety and efficacy of different platelet count thresholds.
- To review risks and alternatives to platelet transfusions in pediatric care.
Main Methods:
- Review of existing literature on platelet transfusion efficacy and safety in children.
- Analysis of studies comparing different prophylactic platelet count thresholds.
- Examination of risks associated with platelet transfusions and potential alternative therapies.
Main Results:
- Limited evidence supports prophylactic platelet transfusions, especially in malignant diseases.
- A platelet count threshold of 10 x 10(9)/L appears as effective as 20 x 10(9)/L for uncomplicated myelo-suppression.
- Platelet transfusions should be reserved for clinically significant bleeding in nonmalignant conditions, with exceptions for neonates.
Conclusions:
- Physicians should critically evaluate the necessity of platelet transfusions in children.
- Lowering prophylactic platelet count thresholds may reduce transfusion risks.
- Alternative therapies are emerging, offering potentially safer options for managing thrombocytopenia.
Abstract:
Platelet transfusions are undoubtedly effective in securing hemostasis in bleeding children with absent or nonfunctioning platelets. They are, however, abused in some circumstances and are not without risk. The use of platelet transfusions to prevent rather than to treat bleeding in children with malignant disease has increased several times over the last two decades. When joining in this widespread practice, physicians should be aware that there is a relatively unimpressive evidence base supporting it and also that for patients with uncomplicated myelo-suppression the most persuasive studies suggest that a threshold platelet count of 10 x 10(9)/L is no less effective than the more customary 20 x 10(9)/L is. Still lower thresholds await evaluation. For children with nonmalignant conditions the use of platelet transfusions should be carefully evaluated on a case-by-case basis, but they should normally be avoided in the absence of clinically important bleeding. Neonates with thrombocytopenia, particularly those with immune disease due to a maternal alloantibody, are considered an exception to this generalization. The serious hazards of platelet transfusions include alloimmunization and the induction of refractoriness, graft-versus-host (GVH) disease, and the transmission of infection, all of which can be life threatening. Less risky alternative therapeutic approaches may become more widely available in the future, including recombinant thrombopoietin and lyophilized heat-treated platelet membrane preparations.